两例免疫功能低下患者的重症COVID-19并发弥漫性肺泡出血
本文报告两例免疫功能低下患者在重症SARS-CoV-2感染背景下出现快速进展的低氧性呼吸衰竭并证实弥漫性肺泡出血(DAH)。DAH是COVID-19的罕见并发症,咯血为其关键症状,临床需对此保持警惕。
要点
- 重症COVID-19患者出现快速进展的低氧性呼吸衰竭时需警惕弥漫性肺泡出血。
- 免疫功能低下患者是COVID-19并发DAH的高危人群。
- 咯血是DAH的关键症状,但属于罕见并发症。
核心结论
- 重症COVID-19在免疫功能低下患者中可并发弥漫性肺泡出血,表现为快速进展的低氧性呼吸衰竭。
研究设计与样本
- 病例报告,报告两例免疫功能低下患者。
主要发现
- 两例免疫功能低下患者在重症SARS-CoV-2感染背景下出现快速进展的低氧性呼吸衰竭并有弥漫性肺泡出血证据。
临床怎么用
- 对重症COVID-19的免疫功能低下患者,若出现快速进展的低氧性呼吸衰竭,应警惕弥漫性肺泡出血的可能。
- 咯血是弥漫性肺泡出血的关键症状,临床应注意识别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diffuse alveolar hemorrhage (DAH) is a severe and potentially life-threatening disease manifestation. In addition to autoimmune diseases such as antineutrophil cytoplasmic antibody-associated vasculitis and anti-glomerular basement membrane syndrome, pulmonary viral infections are known to be culprits of DAH. Health-care providers worldwide in the coronavirus disease 2019 pandemic have been confronted with an unprecedented number of viral lung infections, with great variance in symptoms and severity. Hemoptysis, the key symptom of DAH, is a rare complication. We present two cases of immunocompromised patients with rapidly developing hypoxemic respiratory failure and evidence of DAH in the context of severe acute respiratory syndrome coronavirus 2 infection.
引用
- Löffler C, Mahrhold J, Fogarassy P, et al. Two Immunocompromised Patients With Diffuse Alveolar Hemorrhage as a Complication of Severe Coronavirus Disease 2019. Chest. 2020. PMID: 32622819. doi:10.1016/j.chest.2020.06.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。